Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) to acquire Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. IPN-1087 is a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types.  Fusion intends to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1.

To read more please visit:

https://www.newswire.ca/news-releases/fusion-pharmaceuticals-to-expand-pipeline-with-acquisition-of-ipn-1087-a-small-molecule-targeting-ntsr1-from-ipsen-884009654.html

Source: Fusion Pharmaceuticals Inc.